Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Italian firm Olon buys Ricerca Biosciences' chemical division

Acquisition strengthens service offering of Olon SpA for research and manufacturing

BS B2B Bureau  |  Milan, Italy 

Ricerca Biosciences

SpA, the Italy-based active ingredients (API) contract development and manufacturing organisation (CDMO) and generics supplier, has acquired Ricerca Biosciences’ chemical division of the contract research (CRO) and based in Concord, Ohio (USA). This acquisition strengthens the service offering of for the and biotech industry, and to benefits the Ricerca Biosciences customer base by providing large scale manufacturing capabilities in Europe.

“By acquiring a research and manufacturing base in the US, will have the opportunity to accelerate growth by adding new projects and to develop new Generic products for the American market,” commented Paolo Tubertini, CEO of

Luca Mantovani, managing board member, added, "We are delighted to add Ricerca Biosciences to Group, as this strategic step will broaden our contract research and manufacturing services for all our global customers.” 

Ricerca Biosciences is the US-based supporting the development and manufacture of APIs and performance materials in support clinical supply, market development and commercial distribution.  

First Published: Tue, June 13 2017. 17:21 IST
RECOMMENDED FOR YOU

Italian firm Olon buys Ricerca Biosciences' chemical division

Acquisition strengthens service offering of Olon SpA for research and manufacturing

Acquisition strengthens service offering of Olon SpA for research and manufacturing
SpA, the Italy-based active ingredients (API) contract development and manufacturing organisation (CDMO) and generics supplier, has acquired Ricerca Biosciences’ chemical division of the contract research (CRO) and based in Concord, Ohio (USA). This acquisition strengthens the service offering of for the and biotech industry, and to benefits the Ricerca Biosciences customer base by providing large scale manufacturing capabilities in Europe.

“By acquiring a research and manufacturing base in the US, will have the opportunity to accelerate growth by adding new projects and to develop new Generic products for the American market,” commented Paolo Tubertini, CEO of

Luca Mantovani, managing board member, added, "We are delighted to add Ricerca Biosciences to Group, as this strategic step will broaden our contract research and manufacturing services for all our global customers.” 

Ricerca Biosciences is the US-based supporting the development and manufacture of APIs and performance materials in support clinical supply, market development and commercial distribution.  

image
Business Standard
177 22

Italian firm Olon buys Ricerca Biosciences' chemical division

Acquisition strengthens service offering of Olon SpA for research and manufacturing

SpA, the Italy-based active ingredients (API) contract development and manufacturing organisation (CDMO) and generics supplier, has acquired Ricerca Biosciences’ chemical division of the contract research (CRO) and based in Concord, Ohio (USA). This acquisition strengthens the service offering of for the and biotech industry, and to benefits the Ricerca Biosciences customer base by providing large scale manufacturing capabilities in Europe.

“By acquiring a research and manufacturing base in the US, will have the opportunity to accelerate growth by adding new projects and to develop new Generic products for the American market,” commented Paolo Tubertini, CEO of

Luca Mantovani, managing board member, added, "We are delighted to add Ricerca Biosciences to Group, as this strategic step will broaden our contract research and manufacturing services for all our global customers.” 

Ricerca Biosciences is the US-based supporting the development and manufacture of APIs and performance materials in support clinical supply, market development and commercial distribution.  

image
Business Standard
177 22